Pfizer has announced the results of its Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) interim ana...

from SlashGear https://ift.tt/3kaNZaK
via IFTTT
Pfizer has announced the results of its Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) interim ana...
COMMENTS